ALKS Stock Overview
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Alkermes plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.01 |
| 52 Week High | US$33.71 |
| 52 Week Low | US$22.01 |
| Beta | 0.55 |
| 1 Month Change | -12.79% |
| 3 Month Change | -13.51% |
| 1 Year Change | -18.05% |
| 3 Year Change | 17.12% |
| 5 Year Change | -30.91% |
| Change since IPO | 336.55% |
Recent News & Updates
Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
Apr 09Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?
Apr 08
Recent updates
Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
Apr 09Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?
Apr 08Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet
Jan 26Is Alkermes (NASDAQ:ALKS) Using Too Much Debt?
Nov 01Alkermes' (NASDAQ:ALKS) Earnings May Just Be The Starting Point
Nov 01Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly?
Jul 15There Is A Reason Alkermes plc's (NASDAQ:ALKS) Price Is Undemanding
Jun 07Is Alkermes plc (NASDAQ:ALKS) Trading At A 44% Discount?
Apr 10Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?
Mar 20Alkermes upgraded to neutral at BofA on improved risk/reward outlook
Oct 14Alkermes holder Sarissa Capital says it may look to increase its stake
Oct 07Alkermes: Nothing Stands Out As Interesting
Sep 26Health Check: How Prudently Does Alkermes (NASDAQ:ALKS) Use Debt?
Aug 29Alkermes initiated at neutral at Piper Sandler as company in transition
Aug 16Alkermes Q2 2022 Earnings Preview
Jul 26Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 44% Undervaluation?
Jun 27Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?
May 16Alkermes: Turning The Tides Towards Profitability
Apr 16Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?
Feb 07Alkermes plc's (NASDAQ:ALKS) Intrinsic Value Is Potentially 100% Above Its Share Price
Jan 12Shareholder Returns
| ALKS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.1% | -5.0% | -3.5% |
| 1Y | -18.1% | -1.7% | 20.2% |
Return vs Industry: ALKS underperformed the US Biotechs industry which returned -1.8% over the past year.
Return vs Market: ALKS underperformed the US Market which returned 20.9% over the past year.
Price Volatility
| ALKS volatility | |
|---|---|
| ALKS Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALKS's share price has been volatile over the past 3 months.
Volatility Over Time: ALKS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 2,100 | Richard Pops | www.alkermes.com |
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder.
Alkermes plc Fundamentals Summary
| ALKS fundamental statistics | |
|---|---|
| Market cap | US$4.02b |
| Earnings (TTM) | US$519.16m |
| Revenue (TTM) | US$1.66b |
7.8x
P/E Ratio2.4x
P/S RatioIs ALKS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALKS income statement (TTM) | |
|---|---|
| Revenue | US$1.66b |
| Cost of Revenue | US$253.04m |
| Gross Profit | US$1.41b |
| Other Expenses | US$891.21m |
| Earnings | US$519.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | 3.07 |
| Gross Margin | 84.79% |
| Net Profit Margin | 31.21% |
| Debt/Equity Ratio | 24.2% |
How did ALKS perform over the long term?
See historical performance and comparison